Skip to main content

Search
Profile

Jessica A. Pollard, MD

|
Jessica A. Pollard, MD

Hematology-Oncology

On staff since July 2006

Academic Title: Assistant Professor

Research Center: Center for Clinical and Translational Research

"Last fall, I received a first-day-of-kindergarten photo from a former patient, a survivor of multiply recurrent cancer who we thought was very unlikely to be cured. Her clinical course was not easy, and it is the reward of seeing her return to her "normal" life that makes this job so fulfilling. Snapshots like hers are invaluable and are the motivation behind my research and clinical efforts."

Recommendations

FawnaGreat Falls, MT01.03.12
Dr. Jess was such a blessing during our daughters cancer battles. Cancer is such a struggle and Dr. Pollard was always there in every way, she went above and beyond. We persevered and she was along side our family with every treatment and answered every hard question. She helped give us hope as well as fought for a cure. Today our daughter has been cancer free for 4 years and the impact that was left by Dr. Jess will never fade.
FredaPuyallup, WA11.01.11
I can't say enough positive words to describe Dr. Pollard. She makes my son and I feel important and heard every time we see her. She takes her time explaining everything and answering all of my nervous "mom" questions. She was never impatient or short with me. I also trully appreciated that she remembered all of my son's interests over a 5 year period and even information about other family members we spoke of, but she had never met. That is true careing!! Thank you Dr. Pollard!!
RenaeGraham, WA08.24.11
We've been going to Children's since April of 2011 when our son was diagnosed with CML at 10 years old. We've interacted with many doctors, but Dr. Pollard has been the doctor we've seen the most and we love her genuine compassion for our son and our family as well. The doctors here are very special people with huge hearts and we thank them for everything! Braydon, Jake, Renae & Kendra
Recommend Dr. Jessica Pollard

Overview

Board Certification(s)
Pediatrics
Pediatric Hematology-Oncology
Medical/Professional School
Columbia University College of Physicians and Surgery, New York
Residency
Pediatrics, University of Washington, Seattle
Fellowship
Pediatric Hematology-Oncology, Fred Hutchinson Cancer Research Center, Seattle
Research Description

My research interests include the biology of acute myeloid leukemia (AML) and the impact of disease biology on clinical response.

At present, I am better defining the maturational states of hematopoietic precursors in which molecular events contributing to leukemogenesis arise, and have demonstrated that pediatric AML patients with an internal tandem duplication of the FLT3 gene do poorly if the mutation is detected in an immature hematopoietic progenitor population. My ultimate goal is to improve clinical outcomes in AML by enhancing understanding of the biologic events that contribute to leukemogenesis and by determining whether heterogeneity of such events affects clinical response to conventional chemotherapeutics and/or targeted agents like gemtuzumab ozogamicin (GO). I am also exploring methods for enhancing GO efficacy in patients with GO-resistant disease.

Research Focus Area

Cancer

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
Pediatric Research Loan Repayment Program - NIHNIH - NHLBIOct. 1, 2006 - Sept. 30, 2010

Publications

The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.
Pediatric blood & cancer , 2014 Jan: 61(1)81-8
High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
British journal of haematology , 2013 Sep: 162(5)670-7
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2013 Mar 15: 19(6)1620-7
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
Blood , 2012 Apr 19: 119(16)3705-11
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Feb 20: 29(6)704-11
The role of competition in word learning via referent selection.
Developmental science , 2010 Sep 1: 13(5)706-13
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Blood , 2010 Aug 5: 702-10
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Blood , 2010 Aug 5: 116(5)702-10
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Blood , 2010 Mar 25: 2372-9
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Blood , 2010 Mar 25: 115(12)2372-9
Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors.
Pediatric blood & cancer , 2009 Sep: 53(3)375-8
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Blood , 2009 Jun 25: 113(26)6558-66
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Blood , 2006 Oct 15: 2764-9
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Blood , 2006 Oct 15: 108(8)2764-9

Research Funding

Grant TitleGrantorAmountAward Date
Novel Therapeutic Approaches for Pediatric AMLSt. Baldrick's Foundation, Career Development Award 2012 - 2015
Novel Therapeutic Approaches for Pediatric AMLSt. Baldrick's Foundation, Career Development Award 2008 - 2012
Heterogeneity of CD33 expression in pediatric AML and itsSt. Baldrick’s Foundation, Career DevelopmentJan. 1, 2008
Heterogeneity of CD33 expression in pediatric AML and itsCureSearch Research Fellowship AwardJan. 1, 2008
Heterogeneity of CD33 expression in pediatric AML and itsFor JulieFoundationJan. 1, 2008

Primary Office

Seattle Children's
MB.8.501 - Hematology-Oncology
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2106

Additional Offices

Fred Hutchinson Cancer Research Center
FHCRC Box 358080 - MS D2-373
PO Box 19024
Seattle, WA 98109-1024
206-667-4886

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options